Dividendos de PhaseBio Pharmaceuticals

Dividendo controles de criterios 0/6

PhaseBio Pharmaceuticals no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.8%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	US$0
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M

Aug 12

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?

Aug 10

PhaseBio shares surge after inking exclusive license agreement for bentracimab

Jun 17

What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?

Mar 04

If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%

Jan 08

PhaseBio Pharmaceuticals EPS misses by $0.15

Nov 12

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de PHAS.Q han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de PHAS.Q han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de PhaseBio Pharmaceuticals vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de PHAS.Q con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (PHAS.Q)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.6%
Media de la industria (Biotechs)	2.8%
Previsión de analistas en 3 años (PHAS.Q)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de PHAS.Q en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de PHAS.Q en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de PHAS.Q para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que PHAS.Q no ha comunicado ningún pago.

Dividendos de PhaseBio Pharmaceuticals

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc. announced delayed annual 10-K filing

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab.

PhaseBio Pharmaceuticals, Inc. Announces Executive Changes

PhaseBio Pharmaceuticals, Inc. Announces Resignation of John P. Sharp as Chief Financial Officer, Effective November 30, 2022

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

Chiesi Farmaceutici S.p.A. entered into an agreement to acquire all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab for $100 million.

PhaseBio Pharmaceuticals, Inc.(OTCPK:PHAS.Q) dropped from NASDAQ Composite Index

PhaseBio Pharmaceuticals's Securities to Be Delisted from Nasdaq

PhaseBio Pharmaceuticals, Inc. Filed for Bankruptcy

Price target increased to US$18.00

Consensus revenue estimates fall by 68%

PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M

PhaseBio Pharmaceuticals, Inc. Regains Compliance

PhaseBio Pharmaceuticals Receives Non-Compliance Notices from Nasdaq

Consensus forecasts updated

Phasebio Pharmaceuticals, Inc. Announces Successful Pre-Bla Meeting with U.S. Fda for Bentracimab

Price target decreased to US$14.33

PhaseBio Pharmaceuticals, Inc., Annual General Meeting, May 19, 2022

PhaseBio Pharmaceuticals, Inc. Announces Positive Results from Phase 2B Trial for Bentracimab

PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update

PhaseBio Pharmaceuticals, Inc. Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session

Phasebio Pharmaceuticals, Inc. Provides Pemziviptadil (Pb1046) Program Update

Price target increased to US$16.00

Independent Director exercised options to buy US$116k worth of stock.

Independent Director Peter Klein has left the company

Consensus forecasts updated

PhaseBio Pharmaceuticals, Inc. Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of BLA Submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

Phasebio Pharmaceuticals and SFJ Pharmaceuticals Announce Approval of Ind Application in China for Bentracimab

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?

PhaseBio Pharmaceuticals, Inc.(NasdaqGM:PHAS) dropped from Russell 3000E Index

Consensus revenue estimates increase to US$4.07m

Price target decreased to US$12.75

PhaseBio shares surge after inking exclusive license agreement for bentracimab

Consensus EPS estimates increase to -US$2.31

Consensus revenue estimates fall to US$76.8k

Price target increased to US$15.00

PhaseBio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $56 million.

Full year 2020 earnings released: US$3.39 loss per share (vs US$1.43 loss in FY 2019)

Phasebio Pharmaceuticals and Biovectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?

New 90-day high: US$4.45

SFJ Pharmaceuticals and PhaseBio Pharmaceuticals, Inc. Expands Its Pivotal Phase 3 Reverse-It Trial for Its Lead Product Candidate Bentracimab into the European Union

If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%

Price target lowered to US$13.50

New 90-day high: US$4.44

New 90-day high: US$3.80

Analysts lower revenue estimates to US$296.0k

Analysts lower revenue estimates to US$375.0k

Earnings beat expectations, revenue disappoints

PhaseBio Pharmaceuticals EPS misses by $0.15

New 90-day low: US$3.10

Phasebio Pharmaceuticals, Inc. Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab

PhaseBio Pharmaceuticals, Inc. Announces Receipt of Minutes of End-Of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452

PhaseBio Pharmaceuticals, Inc.(NasdaqGM:PHAS) dropped from S&P Global BMI Index

New 90-day low - US$3.22

New 90-day low - US$3.87

Analysts lower revenue estimates to US$542.0k

First half earnings released

Price target lowered to US$14.75

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies